Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and GM-CSF in Androgen Independent Prostate Cancer
NCT00939510Phase 2Completed
- Start
- Jul 2005
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in prostate cancer (PCa). Primary endpoints: Number of Patients With a PSA Response, RECIST-defined Measurable Disease and 1 more. Started Jul 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00939510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939510.